You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site

Continue

Go back

What resources are available to facilitate your patient management?

2017 GOLD COPD guidelines update

The 2017 GOLD COPD guidelines focus on the role of long-acting muscarinic antagonists/long-acting beta2-agonists (LAMA/LABA) dual bronchodilation therapy in the management of patients with COPD, particularly GOLD B and GOLD D patients with severe breathlessness and/or exacerbations. The updated guidelines also detail the importance of choosing the correct inhaler for your patient, whilst reflecting the patient’s ability and overall preference. 1

Download the 2017 Gold COPD update in daily practice leaflet

Reference:

  1. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease (GOLD) 2017.

Trade marks are owned by or licensed to the GSK group of companies. © 2018 GSK group of companies or its licensor. Anoro Ellipta was developed in collaboration with Theravance Inc.